These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 21849247)

  • 1. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Sacco R; Bargellini I; Bertini M; Bozzi E; Romano A; Petruzzi P; Tumino E; Ginanni B; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C
    J Vasc Interv Radiol; 2011 Nov; 22(11):1545-52. PubMed ID: 21849247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
    Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
    J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response.
    Suk Oh J; Jong Chun H; Gil Choi B; Giu Lee H
    J Vasc Interv Radiol; 2013 Apr; 24(4):483-9. PubMed ID: 23452553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles.
    Padia SA; Shivaram G; Bastawrous S; Bhargava P; Vo NJ; Vaidya S; Valji K; Harris WP; Hippe DS; Kogut MJ
    J Vasc Interv Radiol; 2013 Mar; 24(3):301-6. PubMed ID: 23380737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma.
    Kucukay F; Badem S; Karan A; Ozdemir M; Okten RS; Ozbulbul NI; Kucukay MB; Unlu I; Bostanci EB; Akdogan M
    J Vasc Interv Radiol; 2015 Nov; 26(11):1622-9. PubMed ID: 26321015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
    Song MJ; Park CH; Kim JD; Kim HY; Bae SH; Choi JY; Yoon SK; Chun HJ; Choi BG; Lee HG
    Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis.
    Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS
    J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
    Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
    Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma.
    Cheung AH; Lam CS; Tam HS; Cheung TT; Pang R; Poon RT
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):493-498. PubMed ID: 27733318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).
    Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
    J Surg Oncol; 2010 May; 101(6):476-80. PubMed ID: 20213741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Wu X; Chapiro J; Malhotra A; Kothary N
    J Vasc Interv Radiol; 2021 Jan; 32(1):2-12.e1. PubMed ID: 33160827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.
    Makary MS; Kapke J; Yildiz V; Pan X; Dowell JD
    J Vasc Interv Radiol; 2016 Sep; 27(9):1298-1304. PubMed ID: 27499157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.